Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.3420
-0.0580 (-14.50%)
At close: Dec 18, 2025, 4:00 PM EST
0.2751
-0.0669 (-19.56%)
After-hours: Dec 18, 2025, 7:47 PM EST
Cue Biopharma Employees
Cue Biopharma had 41 employees as of December 31, 2024. The number of employees decreased by 12 or -22.64% compared to the previous year.
Employees
41
Change (1Y)
-12
Growth (1Y)
-22.64%
Revenue / Employee
$173,171
Profits / Employee
-$919,098
Market Cap
26.93M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41 | -12 | -22.64% |
| Dec 31, 2023 | 53 | 1 | 1.92% |
| Dec 31, 2022 | 52 | -7 | -11.86% |
| Dec 31, 2021 | 59 | 7 | 13.46% |
| Dec 31, 2020 | 52 | 5 | 10.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CUE News
- 4 hours ago - Cue Biopharma Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors - GlobeNewsWire
- 2 months ago - Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates - GlobeNewsWire
- 4 months ago - Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference - GlobeNewsWire
- 4 months ago - Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - GlobeNewsWire
- 4 months ago - Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - GlobeNewsWire